Autopsy report · NCT00516542

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

“Study was terminated due to lack of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 3 years 6 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

OHSU Knight Cancer Institute

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

letrozole; DHEA; pharmacological study

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
  “Study was terminated due to poor accrual” (98% match in meaning)
• Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension
  “Study has been terminated due to poor accrual.” (95% match in meaning)
• Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
  “Study terminated due to low accrual.” (94% match in meaning)
• Pembrolizumab + Idelalisib for Lung Cancer Study
  “The study was terminated due to poor accrual.” (93% match in meaning)
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
  “Study terminated due to slow/insufficient accrual.” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.